Kailera Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

Kailera Therapeutics

10/08/2026 23:27

Kailera Therapeutics Inc KLRA.OQ KLRA.O is expected to  report resultson August 12 for the period ending June 30 2026

​LSEG's mean analyst estimate for Kailera Therapeutics Inc is for a loss of 75 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The average consensus recommendation for the pharmaceuticals peer group is  "Buy".​
Wall Street's median 12-month price target for Kailera Therapeutics Inc is $52.50, about 181.4% above its last closing price of $18.66
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.67
-0.67
-0.64
Beat
5.5
 2026
​
​​
​
This summary was machine generated August 10 at 22:27 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)